© 2021 MJH Life Sciences and Urology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
February 26, 2021
The RNAi drug nedosiran is a once-monthly subcutaneous injection under investigation for all 3 types of primary hyperoxaluria.
February 09, 2021
FDA new drug application filing expected by the end of 2021.
September 12, 2012
The FDA recently approved the oral androgen receptor inhibitor enzalutamide (Xtandi) for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel (Taxotere).
August 29, 2012
A common enzyme that is easily detected in blood may predict how well patients with advanced kidney cancer will respond to a specific treatment, according to physicians at Duke Cancer Institute, Durham, NC.
August 22, 2012
Due to manufacturing issues, a formulation of the bladder cancer treatment bacillus Calmette-GuÃ©rin is currently unavailable from one manufacturer.
Researchers from New York-Presbyterian Hospital/Weill Cornell Medical Center in New York have successfully developed and tested a new prostate cancer screening method.
August 15, 2012
Fesoterodine fumarate (Toviaz) appears to reduce urge urinary incontinence in patients with overactive bladder who had a suboptimal response to tolterodine tartrate extended release (Detrol LA), according to a phase IV study.
August 01, 2012
Interim data from a phase III trial of a novel radiation agent in men with castration-resistant prostate cancer (CRPC) showed the agent's efficacy to be significantly sufficient to bring the trial to a halt at a planned interim analysis so as to be able offer the agent to men in the placebo arm.
July 18, 2012
The diabetes drug pioglitazone (Actos) was associated with a 22% increased risk of developing bladder cancer in a recent study, supporting earlier research findings of a link between the drug and bladder cancer.
July 11, 2012
American Medical Systems (Minnetonka, MN) has signed a co-development agreement with Allergan, Inc. to jointly develop and seek regulatory approval for the delivery of onabotulinumtoxinA (Botox) using the AMS JetTouch system for treatment of overactive bladder.
The FDA has approved the once-daily oral beta-3 adrenergic agonist mirabegron (Myrbetriq) for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
July 05, 2012
Testosterone replacement therapy may result in weight reduction and improvement in symptoms of metabolic syndrome, according to separate studies presented at the Endocrine Society annual meeting in Houston.
July 01, 2012
Treatment with the dual 5-alpha- reductase inhibitor dutasteride (Avodart) does not compromise the utility of PSA to detect progression of disease in patients with low-risk localized prostate cancer who are being managed with active surveillance.
June 27, 2012
Two clinical trials testing experimental drugs aimed at restoring the immune systemâ€™s ability to spot and attack cancer have shown promising early results in patients with kidney cancer, as well as those with advanced non-small cell lung cancer and melanoma.
Janssen Research & Development, LLC recently submitted a supplemental new drug application to the FDA for abiraterone acetate (ZYTIGA) intended to extend the use of abiraterone administered with prednisone to include the treatment of patients with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and before chemotherapy.
June 20, 2012
The investigational agent radium-223 dichloride significantly increased overall survival in patients with castration-resistant prostate cancer with bone metastases, updated results of a recent phase III trial showed.
June 13, 2012
New data have added to previous evidence that the use of pioglitazone (Actos) appears to be associated with an increased risk of incident bladder cancer among patients with type 2 diabetes, Canadian researchers recently reported.
June 06, 2012
Six months of treatment with the targeted androgen biosynthesis inhibitor abiraterone (ZYTIGA), in addition to standard hormonal therapy before prostatectomy, eliminated or nearly eliminated cancer in one-third of men with localized high-risk prostate cancer, a recent study found.
June 01, 2012
Elevated pretreatment androgen levels correlate with significantly better overall survival in men with castration-resistant prostate cancer, regardless of treatment, a recent post hoc analysis of a large randomized trial showed.
Phosphodiesterase type-5 inhibitors are safe and effective, alone or in combination with alpha-blockers, against lower urinary tract symptoms secondary to BPH, according to a recent systematic review and meta-analysis.